DIA Jumps on Brexit Bandwagon

November 2, 2017
Philip Ward

Philip Ward is ACT's European editor, phone +44 1244 538583, philipward1@btconnect.com

Applied Clinical Trials

The considerable uncertainty caused by Brexit is proving a goldmine for conference organizers, it seems. The Drug Information Association (DIA) is the latest group to put together a meeting about this hot topic.

“Brexit will have a considerable impact on the regulation and supply of medicines to patients,” noted the DIA in a statement. “With the time frame for Brexit fast elapsing, governments, regulators, companies, healthcare systems, and patients are all seeking to prepare for the “known unknowns” and to brace for the “unknown unknowns”. However, information is scarce and not always accessible or confirmed.”

At its meeting to be held in London on December 8, DIA plans to bring stakeholders together to share their knowledge about operational and strategic measures being taken to prevent or minimize the impact of Brexit.

According to the organizers, “With the clock ticking, stakeholders will consider explicitly in this conference the dimension of time in shaping what opportunities for action companies-and indeed all stakeholders-must consider.”

The closing session, called Brexit time check: "what’s next for medicines?”, will be chaired by ACT columnist Peter O’Donnell. The aim is to investigate the broader level vision of what’s coming next in the Brexit schedule of change.

For the full program and further details, click here.

Philip Ward is the European Editor for Applied Clinical Trials.